Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China

被引：0
|
作者：
Yake Lou
Tianyang Hu
Jing Huang
机构：
[1] The Second Affiliated Hospital of Chongqing Medical University,Department of Cardiology
[2] The Second Affiliated Hospital of Chongqing Medical University,Precision Medicine Center
来源：
American Journal of Cardiovascular Drugs | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：47 / 57
页数：10
相关论文
共 50 条
  • [31] Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
    Fauchier, Laurent
    Lamblin, Nicolas
    Tardu, Jean
    Bellier, Lucile
    Groyer, Harinala
    Ittah, Deborah
    Chollet, Julien
    Linden, Stephan
    Levy, Pierre
    [J]. PHARMACOECONOMICS-OPEN, 2024, 8 (01) : 19 - 30
  • [32] A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
    Tafazzoli, Ali
    Reifsnider, Odette S.
    Bellanca, Leana
    Ishak, Jack
    Carrasco, Marc
    Rakonczai, Pal
    Stargardter, Matthew
    Linden, Stephan
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2023, 24 (09): : 1441 - 1454
  • [33] A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
    Ali Tafazzoli
    Odette S. Reifsnider
    Leana Bellanca
    Jack Ishak
    Marc Carrasco
    Pal Rakonczai
    Matthew Stargardter
    Stephan Linden
    [J]. The European Journal of Health Economics, 2023, 24 : 1441 - 1454
  • [34] Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction
    Parizo, Justin T.
    Goldhaber-Fiebert, Jeremy D.
    Salomon, Joshua A.
    Khush, Kiran K.
    Spertus, John A.
    Heidenreich, Paul A.
    Sandhu, Alexander T.
    [J]. JAMA CARDIOLOGY, 2021, 6 (08) : 926 - 935
  • [35] Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction
    Rungroj Krittayaphong
    Unchalee Permsuwan
    [J]. American Journal of Cardiovascular Drugs, 2022, 22 : 577 - 590
  • [36] Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective
    Lin, Xiaohui
    Lin, Minhua
    Liu, Maobai
    Huang, Weiying
    Nie, Xuekun
    Chen, Zichun
    Zheng, Bin
    [J]. JOURNAL OF THORACIC DISEASE, 2022, 14 (05) : 1588 - 1597
  • [37] Cost-Utility Analysis of Combination Empagliflozin and Standard Treatment Versus Standard Treatment Alone in Thai Heart Failure Patients with Reduced or Preserved Ejection Fraction
    Krittayaphong, Rungroj
    Permsuwan, Unchalee
    [J]. AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2022, 22 (05) : 577 - 590
  • [38] Research in brief: Empagliflozin for patients with heart failure and preserved ejection fraction
    Pooni, Rajan S.
    Ismail, Tevfik F.
    [J]. CLINICAL MEDICINE, 2022, 22 (01) : 75 - 76
  • [39] Cost-Effectiveness of Medical Therapy for Heart Failure With Mildly Reduced and Preserved Ejection Fraction
    Dixit, Neal M.
    Truong, Katie P.
    Vaduganathan, Muthiah
    Ziaeian, Boback
    Fonarow, Gregg C.
    [J]. JACC-HEART FAILURE, 2024, 12 (07) : 1226 - 1237
  • [40] Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
    Isaza, Nicolas
    Calvachi, Paola
    Raber, Inbar
    Liu, Chia-Liang
    Bellows, Brandon K.
    Hernandez, Inmaculada
    Shen, Changyu
    Gavin, Michael C.
    Garan, A. Reshad
    Kazi, Dhruv S.
    [J]. JAMA NETWORK OPEN, 2021, 4 (07) : E2114501
12345